# The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients

Study · id `cardio:ct-nct05579418` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05579418](<https://clinicaltrials.gov/study/NCT05579418>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05579418

Browse, organ or system: Heart; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 350 participants.

## Technical summary

Registry record NCT05579418. Randomized; no masking; primary purpose treatment. Start 2022-11-01 (anticipated); primary completion 2024-10-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 350 participants (planned count; ClinicalTrials.gov record NCT05579418, source copy `cardio:ctgov-nct05579418-2022-10-13`, retrieved 2026-10-26)
- Planned start: 2022-11-01 (anticipated) (ClinicalTrials.gov record NCT05579418, source copy `cardio:ctgov-nct05579418-2022-10-13`, retrieved 2026-10-26)
- Primary completion: 2024-10-30 (anticipated) (ClinicalTrials.gov record NCT05579418, source copy `cardio:ctgov-nct05579418-2022-10-13`, retrieved 2026-10-26)
- Completion: 2024-10-30 (anticipated) (ClinicalTrials.gov record NCT05579418, source copy `cardio:ctgov-nct05579418-2022-10-13`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05579418-2022-10-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
- Condition: STEMI
- Condition: Dyslipidemias
- Intervention (Drug): Evolocumab
- Lead sponsor: Hamad Medical Corporation
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry condition terms include this condition: ST-elevation heart attack (STEMI) (`cardio:stemi`)
- Registry intervention name matches this record: Evolocumab (`cardio:evolocumab`)
- Registry lists this organization as the lead sponsor: Hamad Medical Corporation (`cardio:org-hamad-medical-corporation`)

## Provenance

Content hash: ff8b819cab7b78c1c240799fa333ca231994d0e35ae7b0a982407095c33ce56f
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
